Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245102 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 1
- Study location
NCT00245102 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 147 participants, above the 75-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (96% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00245102, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions Studied
Interventions
- DRUG sorafenib tosylate
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245102
The ClinicalTrials.gov registry entry for NCT00245102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (96% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which sorafenib tosylate is the first listed.
NCT00245102 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00245102 about?
NCT00245102 is a clinical study titled "Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma". This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00245102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2005-09. Estimated completion is 2011-03.
What conditions does trial NCT00245102 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Ovarian Sarcoma, Recurrent Uterine Sarcoma, Adult Angiosarcoma.
What interventions are being tested in trial NCT00245102?
The interventions under investigation include: sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00245102?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00245102 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
-
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Adult Soft Tissue Sarcoma
All registered trials for this condition
Stage III Adult Soft Tissue Sarcoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.